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2Abstract
Current evidence shows that epigenetic regulation of gene expression involves methylation of
CpG islands, as well as deacetylation, methylation and phosphorylation of histones. These are
key mechanisms in gene silencing and have a crucial role in the pathogenesis of several types of
cancer, namely Acute Lymphoblastic Leukemia.
With this project, we intend to study the therapeutic potential of the hypomethylating agent,
Decitabine, and the histone deacetylase inhibitor, Trichostatin A in acute lymphoblastic leukemia
cell lines, both as single agents and in association.
For this purpose, two T-ALL cell lines, one derived from a patient in the initial stages of
disease, MOLT-3 cells, and another obtained from the same patient in relapse, MOLT-4 cells,
were incubated with increasing concentrations of Decitabine and/or Trichostatin A during
different periods of time. Cell density and viability were analyzed by Trypan Blue exclusion
assay and Alamar Blue test. Susceptibility to cell death by apoptosis was evaluated by flow
cytometry using Annexin V. The efficacy of the epigenetic modifiers was determined by the
methylation profile of the p15, p16 and p53 tumor suppressor genes using methylation-specific
PCR
The results obtained suggest that Trichostatin A as a single agent has an antiproliferative and
cytotoxic effect in a dose and time dependent manner. On the other hand, Decitabine alone has a
modest effect under the tested conditions. However, when Decitabine was added to cell cultures
previously incubated with Trichostatin A, a synergistic antiproliferative and pro-apoptotic effects
were observed. Concomitantly, changes in the methylation pattern of p15 were shown as the
result of the incubation with Decitabine and Trichostatin A. For both cell lines the maximal
3hypomethylating effect was obtained with the association of both molecules. p16 gene was
shown to have low methylation levels even in control conditions and was not significantly
modified by drugs.
As single agents or in association, epigenetic modulators may provide a new and effective
therapeutic approach in T-cell acute lymphoblastic leukemia. However, therapeutic success
seems to be highly dependent on the agents in use, the specific cancer and, as shown in this
work, on the schedule of drugs administration.
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Introduction
Epigenetics could be defined as the “information heritable during cell division other than the
DNA sequence itself” (Feinberg, 2007). It has important functions in maintaining genome
integrity and cell identity (Weber et al., et al., 2007). Two of the most studied epigenetic
phenomena are DNA methylation and histone tail modifications (Yoo CB et al.,  2006),  called
“histone code” (Figure 1). In humans, DNA methylation occurs in cytosines that precede
guanines; these are called dinucleotide CpGs. CpG sites are not randomly distributed in the
genome; instead, there are CpG rich regions known as CpG islands, which span the 5’ end of the
regulatory region of  approximately 50% of  genes.  These islands are  usually  not  methylated in
normal cells. The methylation of particular subgroups of promoter CpG islands can, however, be
detected in normal tissues (Esteller M., 2008).
DNA is methylated by DNA methyltransferases (DNMTs) at the 5-position (C5) of the
cytosine ring, almost exclusively in the context of CpG dinucleotides, which are poorly
represented in the genome-overall due to spontaneous deamination of 5-methylcytosine into
thymine. Low levels or a lack of DNA methylation in the promoter region is correlated with
5active gene expression. By contrast, methylation near the transcription start site inhibits-gene
expression. This is mediated by the recruitment of transcription repressors such as methyl-
binding proteins (MBDs), which are part of a large complex that includes histone deacetylases
(HDACs). DNA methylation can-also inhibit transcription directly by blocking binding of
transcriptional factors such as MYC5.
Figure 1: Patterns of epigenetic modifications in normal and cancer cells. Although DNA
methylation (A) and histone acetylation (B) can be found in normal cells, the patterns of such
epigenetic modifications is profoundly altered in cancer cells. In normal cells, promoter regions
located upstream of the genetic sequence are unmethylated, whereas in cancer cells methylation
occurs preferentially at the CpG islands located in the regulatory regions of certain genes, such
as tumor – suppressor genes, silencing them. Chromatin and histone modifications (de-
acetylation and methylation) also repress gene expression by associating nucleosomes to the
promoter regions and recruiting other enzymes to form the repressive complex. (Adapted from
Gal-Yam et al. 2008)
6DNA is wrapped around a core of eight histones to form nucleosomes, the smallest structural
unit of chromatin. The basic amino terminal tails of histones protrude out of the nucleosome and
are subject to posttranslational modifications, including acetylation by histone acetyltransferases
(HATs) and histone methylation by histone lysine methyltransferases (HMTs). These
modifications influence how tightly or loosely the chromatin is compacted and, thereby, play a
regulatory role in gene expression. The acetylation of lysine residues on histones H3 and H4 is
correlated with active or open chromatin, which allows various transcription factors access to the
promoter regions of target genes (Santos Rosa et al., 2005; Quina et al., 2006). By contrast,
deacetylation of lysine residues by HDACs results in chromatin compaction and inactivation of
those genes (Yoo CB et al., 2006)
Disruption of the mechanisms that define such legacy may lead to an inappropriate gene
expression or gene silencing and, consequently, to ‘epigenetic diseases’, including
developmental disorders, neurodegenerative diseases and cancer. (Jones et al., 2001; Egger et al.,
2004). It is currently well known that several types of cancer exhibit an aberrant pattern of
methylation, with both global hypomethylation and local gene-specific hypermethylation and
chromatin modifications (Jones et al.,  2002; Herman et al., 2003; Lund et al., 2004; Feinberg ,
2007). Examples of genes affected by these processes include P15/INK4B and p16/INK4A
tumor suppressor genes, which control the G1/S cell cycle transition by inhibiting cyclin-
dependent kinases.  p16 is also one of the most frequently inactivated tumor-suppressor genes in
cancer and together with p15, is one of the most well characterized cell cycle regulatory genes.
Both are epigenetically silenced by DNA hypermethylation, a mechanism that may play an
important role in several hematological malignancies as Chronic Myeloid Leukemia (CML),
Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) (Baylin et al.,
72000; Esteller, 2002; Galm et al., 2005; Chim et al., et al., 2007). Together with genetic
modifications, aberrant epigenetic regulation allows cancer cells to escape growth, differentiation
and death control mechanisms, giving rise to the malignant phenotype (Jones et al., 1999; Baylin
et al., 2000; Herman et al., 2003; Feinberg et al., 2004).
The main processes used to initiate and sustain epigenetic silencing – DNA methylation and
histone modification – may occur at different stages of carcinogenesis and contribute to both
cancer initiation and progression. They interact at several levels (Esteller, 2007): on one hand,
histone de-acetylation is more prone to happen in sites previously subjected to DNA methylation
through MBDs that recruit HDACs; on the other hand, HDACs contribute to the epigenetic
stabilization of the repressive patterns by recruiting DNA-methyltransferases. (Altucci et al.,
2005).
In contrast to genetic modifications, epigenetic alterations, although heritable (Martin et al., et
al., 2007), are transient and can be reversed to some extent. This has encouraged the
development of new therapeutic tools: the “epi-drugs” (Di Gennaro et al., 2004; Altucci et al.,
2005; Yoo et al., 2006). In fact, several molecules have shown ability to inhibit and reverse DNA
methylation, including hypomethylting agents Azacytidine, Decitabine (5-aza-2’-deoxycytidine
or DAC), Zebularine and even certain constituents of dietary products such as green tea (Fang et
al., 2003). Another class of drugs, acting primarily on histone acetylation has shown great
therapeutic potencial. Several HDAC-inhibitors (HDACis) were identi?ed, such as butyric acid,
suberoy-lanilide hydroxamic acid (SAHA), Trichostatin A (TSA), cyclic tetrapeptides and
benzamides (Yoo et al., 2006). Both classes of drugs have proven their safety and therapeutic
value (Egger et al., 2004). Azacytidine (Vidaza®, Pharmion, Boulder, CO, USA) and Decitabine
(Dacogen™, SuperGen Inc., Dublin, CA, USA, and MGI Pharma Inc., Bloomington, MN, USA)
8are approved for clinical use in Myelodysplastic syndrome (MDS) of all FAB subtypes, in low-
dose schedules, having reached good results specially in patients with a high-risk profile
(Silverman et al.,  2005;  Issa,  2005;  Gaterman et al., et al., 2007). Phase III trials have
demonstrated that Azacytidine elicits a 60% total response and Decitabine, a 30% total response.
The average duration of these responses was 14 months for Azacytidine and 9 months for
Decitabine (Silverman et al., 2002). Other molecules have shown therapeutic efficacy and safety,
such as SAHA (Vorinostat) which was approved for treatment of the cutaneous manifestations of
cutaneous T-cell lymphoma in 2006. Knowledge about action mechanisms may open doors to
more effective use of these agents, whether isolated or as part of a therapeutic association
(Strausberg, et al., 2004). In fact, several therapeutic trials, using the combination of
hypomethylating agents and HDAC inhibitors, have shown that this association has synergistic
properties in several types of cancer, including leukemias. (Gore, 2005)
Acute lymphoblastic leukemia is the most common type of leukemia in children. Only 20-40%
of adults with ALL are cured with current regimens – which include induction, consolidation,
maintenance, and central nervous system prophylaxis schemes – with cytotoxic agents. As in
other hematologic malignancies (with the exception of Ph+ CML) no significant therapeutic
advances have been accomplished recently and failure to chemotherapy (chemoresistance) and,
consequently, relapse, may occur. On the other hand, death may result from uncontrolled
infection or hemorrhage. These facts make the pursuit of new therapeutic targets/strategies an
important task.
9Aims
 In this study, we intend to evaluate the therapeutic efficacy, and the mechanisms involved, of
the hypomethylating agent, Decitabine (5-aza-2’-deoxycitidine), and of the HDAC inhibitor,
Trichostatin A, in T-ALL cell lines in culture, as single agents and in  association.
Materials and Methods
Cell Lines, cell viability and cell density
Human T-ALL cell lines,  MOLT-3 (derived from a T-ALL patient in the initial stages of
disease) and MOLT-4 (obtained from the some patient at relapse) cells, provided by American
Type Culture Collection (ATCC), Manassas-USA, were maintained in culture, in 5% CO2
atmosphere at 37°C, in RPMI-1640 medium (L-glutamine 2mM, HEPES-Na 20 mM, NaHCO3 2
g/L, penicilin 100 U/ml and streptomycin 100 ?g/ml, pH 7.4) (Sigma) supplemented with 10%
fetal calf serum (FCS, GIBCO). To determine the dose-dependent changes, both cell types were
cultured  in  the  absence  and  presence  of   Trichostatin  A  (Pharmion,  Boulder,  CO,  USA)  in
concentrations ranging from 1 nM to 100 ?M  and/or  Decitabine  (MGI  Pharma  Inc.,
Bloomington, MN, USA) (10 nM to 500 ?M) for up to 72 hours. No further addition of drug was
made after the first dose.
For treatment with Decitabine and Trichostatin A, MOLT-3 and MOLT-4 cells were seeded at
low density (0,5x106/well). Cell proliferation/density was assessed by cell counting in a
Neubauer chamber and cell viability was estimated by trypan blue staining each 24 hours, during
72 hours.
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Morphological analysis
Cells were incubated in the absence and presence of effective concentrations of Trichostatin as
determined by cell viability studies described above. Cell morphology was evaluated by light
microscopy examination of May-Grünwald-Giemsa stained cells using a Leitz Dialux 20
microscope fitted out with a photographic chamber.
Flow cytometry assays
Cell death was analysed by flow cytometry, staining the cells with Annexin V (AV) (BD
Biosciences), labelled with the fluorescente probe fluorescein isothyocianate (FITC). Cells
cultured in the absence or in the presence of the drugs were washed (centifuged at 300 xG for 5
min) and incubated for 10 min at 4ºC in 440 mL Annexin buffer (Immunotec, Quebec, Canada)
containing 5 ?L FITC-labeled Annexin V. Then, cells were washed with phosphate buffer (PBS)
and ressuspended in the same buffer. The results were analysed on a FACScan cytometer (BD
Biosciences, Heidelberg, Germany) equipped with an argon ion laser emitting a 488 nm beam,
which was the excitation source for Annexin V-FITC . Green fluorescence of Annexin V was
collected with a 525-nm band pass filter. The results are expressed in % of viable cells and
apoptotic cells (Darzynkiewicz et al., 1997).
Bisulfite Modification and Methylation-Specific PCR (MSP)
DNA extraction of cells incubated in the absence and presence of effective concentrations of
Trichostatin A and Decitabine was performed by anion-exchange resin technology (Blood & Cell
Culture DNA Kit, Qiagen). The DNAs were modified with sodium bisulfite (EpiTect Bisulfite
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Kit, Qiagen) and methylation-specific PCR were carried out as previously described (Herman et
al. 1996; Yeh, et al. 2003) with few modifications. Methylation-specific PCR was performed
using primer sequences included in Table I.
Table I. Primer Sequences for Methylation-Specific PCR
Primer Sequence
Methylated MS-PCR
p15F (forward) 5'-TAGTGAGGATTTCGCGACGC-3'
p15R (reverse) 5'-ACGACCGATCGTTAACTCCG-3'
p16F 5'-TTATTAGAGGGTGGGGCGGATCGC-3'
p16R 5'-GACCCCGAACCGCGACCGTAA-3'
p53F 5'-ATTTACGGTATTAGGTCGGC-3’
p53R 5'-ACACGCTCCCAACCCGAACG-3'
Unmethylated MS-PCR
p15F 5'-GTTAGAGTGAGGTGGGGTAGTGAGGATTTTGTGATGT-3’
p15R 5'-TACAATAACCAAACAACCAATCATTAACTCCA-3'
p16F 5'-TTATTAGAGGGTGGGGTGGATTGT-3'
p16R 5'-CAACCCCAAACCACAACCATAA-3'
p53F 5'-TTTAAAATGTTAGTATTTATGGTATTAGGTTGGT-3'
p53R 5'-CATCATAAAAAACACACTCCCAACCCAAACA-3'
Briefly, modified DNAs were amplified in 20 ?L of mixture containing 5 mM MgCl2, 100 ?M
of each primer, 0,2 mM dNTPs and 2.5 units of Taq polymerase (Quiagen). Reactions were
performed at 60º C  and 65º C annealing temperatures respectively for Mp15, Mp16 and Up16,
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and for Up15, Mp53 and Up53. PCR products were resolved on 4% agarose gels, stained with
ethidium bromide and visualized under UV illumination.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism software, version 5.00 for Windows
(GraphPad Software, San Diego, CA, USA). Non linear regression of data was performed in
order to obtain dose – effect curves and estimation of IC50. Two – way ANOVA with Bonferroni
test was applied to available data. Statistical significance was considered for p<0,05.
Results
Starting with a cell density of 0,5x106 cells/mL, it was observed that Trichostatin A leads to a
decrease in cell viability and density in a dose, time and cell type dependent manner (Figure2).
Reduction of cell density (figure 2-B) and viability (figure 2-A) in both cell lines reached 50%
(IC50) with Trichostatin A at concentration of 250 nM. Decitabine, however, showed a more
modest effect in both cell lines (Figure 3), especially in MOLT-4, where the reduction of cell
viability (Figure 3-A) attained only 20% for the highest concentration tested. In the case of
MOLT-3 cells, the same concentration of Decitabine leads to 40% reduction in cell viability,
indicating that MOLT-4 cells are more resistante to Decitabine than MOLT-3.
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A    ___________MOLT-3___________        ___________MOLT-4___________
B    ___________MOLT-3___________        ___________MOLT-4___________
Figure 2: Trichostatin A dose – and time – response curves. The effect of Trichostatin A in
MOLT-3 (left column) and MOLT-4 (right column) cells was evaluated through the
determination of cell viability (A) and cell density (B) at  24, 48 and 72 hours of incubation with
increasing concentrations of Trichostatin A, as described in methods and materials. The viability
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data is expressed in percentage (%) and represents the mean±SD of 3 independent experiments.
Density is expressed in absolute numbers of viable cells per milliliter.
Although Decitabine failed to show the same cytotoxic efficacy, compared with those observed
with Trichostatin A , it proved to have an anti-proliferative effect in both cell lines (Figure 3B).
Therefore, Decitabine may have a role in delaying proliferation, but is not capable of inducing
apoptosis as a single agent.
A    ___________MOLT-3___________        ___________MOLT-4___________
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B    ___________MOLT-3___________        ___________MOLT-4___________
Figure 3: Decitabine dose– and time – response curves. The effect of Decitabine in MOLT-3
(left column) and MOLT-4 (right column) cells was evaluated through the determination of cell
viability (A) and cell density (B) at 24, 48 and 72 hours of incubation with increasing
concentrations of Decitabine as represented. The viability data is expressed in percentage (%)
and represents the mean±SD of 3 independent experiments. Density is expressed in absolute
numbers of viable cells per milliliter.
Despite its smaller effect, we hypothesized that Decitabine could serve as an adjuvant for the
apoptotic action of Trichostatin A. With this in mind, we performed association experiments,
shown in figures 4 and 6. As shown in figure 4, simultaneous association of drugs did not
improve the result obtained with Trichostatin A alone. Similarly, sequential incubation with
Decitabine before Trichostatin also failed to prove to be more effective than either agent alone.
However,  a  very  significant  reduction  of  cell  viability  was  observed  when  TSA  was
administrated to cell culture previously to DAC. In this condition, we observe a potentiation of
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the cytotoxic effect. In fact, a reduction of cell viability above 80% in both cell lines is observed
(figure 4).
Figure 4: Effect of the association of Decitabine and Trichostatin A on MOLT-3 and
MOLT-4 cells viability. The effect of Trichostatin A and Decitabine on MOLT-3 and MOLT-4
cells viability was evaluated through the determination of cell viability at 24 hours, as described
in  methods  and  materials.  A  synergistic  effect  was  observed  when  cells  were  exposed  to
Decitabine after 4 hours of incubation with Trichostatin A, but not when exposure was made
simultaneously or reversely. Data is expressed in percentage (%) of cells and represents the mean
± SD of 2 independent experiments. “Simult.” Refers to the simultaneous addition of drugs;
“seq.” refers to the sequential incubation of cells with one drugs and, 4 hours later, with the
other.
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Optical microscopy was used to further characterize the cytotoxic effects observed. Figure 5
shows the morphology of cell smears stained with May-Grünwald-Giemsa before (Figure 5A)
and after (Figure 5B) treatment with Trichostatin A. As it can be observed, cells show
morphological characteristics typical of cell death by apoptosis, such as cell contraction, nuclear
fragmentation, blebbing and apoptotic bodies (Figure 5B). These results were confirmed in flow
cytometry studies (Figure 6).
A       B
Figure  5: Morphological analysis of MOLT-3 cells after treatment with Trichostatin A.
Control cells are shown on the right panel (A) and cells treated with Trichostatin A on the right
(B). As we can see, there is morphological evidence of cell death by apoptosis, such as cellular
contraction, nuclear fragmentation, blebbing and apoptotic bodies’ formation. Cell smears were
stained with May-Grünwald-Giemsa. Amplification: 500x
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A
              B               C
  D               E
Figure 6: Analysis of cell viability and death by flow cytometry. The figure represents the
reduction of cell viability as result of the exposure of MOLT-3 (A, B and C) and MOLT-4 (A, E
and F) cells to Trichostatin (TSA) alone and in combination with Decitabine (DAC). Viability
and death was studied by flow cytometry using Anexin V staining as referred in material and
methods. Quantification graphics (A) and dot plots (B-E) are shown: control situations for
19
MOLT-3 and MOLT-4 are represented in B and D; C and E are examples of dot plots obtained
using the sequential incubation with TSA and DAC in MOLT-3 and MOLT-4 cells, respectively.
All results were obtained after the incubation of cells for 24 hours. “Simult.” Refers to the
simultaneous addition of drugs; “seq.” refers to the sequential incubation of cells with one drugs
and, 4 hours later, with the other.
As shown in figure 6, the synergistic effect obtained with the specific incubation sequence
described above was translated into an increase in the number of Anexin V positive cells (hence,
in early stages of apoptosis) as early as 24 hours after initial incubation. Although the
concentration of TSA was below the IC50, the apoptotic effect of the association was superior to
the highest concentration of either drug alone.
In order to characterize some of the molecular events underlying such response, we chose to
study some genes involved in cell cycle regulation and cell proliferation; p15, p16 and the cell
guardian gene, p53. Having hypothesized that these genes could be silenced in this cell lines,
thus contributing to the malignant phenotype, we analyzed their methylation status before and
after the incubation with Decitabine and/or Trichostatin A (figure 7)
Changes in the degree of methylation of p15 were observed as the result of the incubation with
Decitabine and Trichostatin A. Amplification was successful as shown in figure 7A, where a
well defined band near 150 base pairs is evident, as expected for this gene. The p16 gene was
shown to have low methylation levels even in control conditions and was not significantly
modified by the incubation. No results are available for p53, despite the evident positive control.
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A
Figure 7: MSP electrophoresis
analysis of methylation status of p15,
p16 and p53 tumor suppressor genes.
The figure show p15 (A), p16 (B) and
p53 (C) methylation status in MOLT-3
and MOLT-4 cells untreated (control)
and  after  treatment  with  TSA  (100  nM)
and DAC (5 ?M) alone and in association
(TSA  +  DAC).  The  figure  also  show  a
positive and negative control for each
gene. “M” labels the molecular weight
lane.
B
C
The quantification of the effect of Decitabine and Trichostatin A on p15 methylation status is
represented in figure 8. Besides the induction of cell apoptosis, both drugs show an
hypomethylating effect. In fact, TSA and DAC as single agents effectively reduce p15
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methylation. However, DAC, which acts primarily on the methylation process, proved to be
more effective than TSA. No improvements on this result were achieved with the simultaneous
association of drugs, where the demethylating effects were similar to Decitabine alone.
Figure 8: Quantification of the intensity of p15 MSP electrophoresis bands. As shown,
methylation of p15 is reduced after the exposure to each drug. The maximal demethylation was
achieved with Decitabine in monotherapy and with the association of Decitabine and
Trichostatin. Results were obtained after 24 hours of incubation; association assay was carried
out with simultaneous addition of drugs only. TSA concentration used: 100 nM; DAC
concentration used: 5 ?M.
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Discussion and conclusion
Only in recent years, we have begun to fully understand the mechanisms underlying epigenetic
events and how they, when disturbed, contribute to the development of leukemia and other
malignancies (Jones et al., 2002; Feinberg et al., 2004; Jiang et al., 2004; Goldberg et al., et al.,
2007). As a concept, epigenetics added an additional level to the complex gene expression
regulation network . Biological complexity not only depends on the number of genes, but also on
how those genes are expressed, which is largely due to epigenetic mechanisms (Whitelaw et al.,
2006). Also, disruption of mechanisms that regulate both genetic and epigenetic processes
cooperate to produce disease. In most sporadic cancers, age is one important risk factor.
Although the increase in cancer risk has been classically attributed to the accumulation of
mutations over time, a complementary explanation is that age process itself disrupts the
epigenetic pattern, as shown for RhoB (Yoon et al., et al., 2007). This could explain why the
most common disorders that involve complex genetics are of adult onset, including cancer (Jones
et al., 2002; Feinberg et al., 2004; Ptak et al., 2008). However, many questions about the relation
between ageing and epigenetics remain unanswered (Fraga et al., 2007).
Epigenetics seems to be a major role-player in both hematopoiesis and hematologic
malignancies (Ivascu et al., 2007; Galm et al., 2005). In ALL and AML, the ALL1 (or MLL)
gene can fuse with one of more than 50 genes. Mutation of ALL1 leads to the formation of
chimeric proteins that, through anomalous interference with histone methylation/acetylation and
RNA processing, deregulate homeobox genes, EPHA7 gene (which encodes a tyrosine kinase
receptor), and microRNA genes (Croce, 2008). In fact Roman-Gomez and collaborators have
shown that in ALL the genome methylation profile – including p14, p15 and p16 genes – is an
independent prognostic factor in predicting disease-free survival and overall survival in ALL
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(Roman-Gomez et al., 2004). Hypermethylation of p16INK4A seems  to  occur  predominantly  in
pre-malignant stages; the consequent loss of gene function allows cells to bypass an early cell
cycle checkpoint, allowing later genetic (or epigenetic) alterations (Baylin et al., 2000). Other
relevant targets of epigenetic silencing in cancer include the cyclin-dependent kinase inhibitor
p21WAF1/CIP1 (Ocker et al., 2007), the apoptosis related ligand/receptor TRAIL and the p53-
related gene p73 (Altucci et al., 2005; Baylin et al., 2000 Galm et al., 2005, Baylin et al., 2007).
They play important roles in all stages of the malignant process and underlie the common
hallmarks of cancer - cell growth and differentiation, cell cycle control, DNA repair,
angiogenesis, migration, apoptosis resistance and even chemo-resistance (Hanahan et al., 2000).
These facts, together with the results, make ALL an attractive target for therapeutics with epi-
drugs.
In this study, we have shown that the hypomethylating agent Decitabine and the HDAC
inhibitor Trichostatin A are effective in reducing cell density and viability of ALL cells lines in
culture. Although initiation and progression events in carcinogenesis may differ significantly, we
have shown that Decitabine and especially Trichostatin A are effective in cells isolated from
ALL patients at disease presentation (MOLT-3) as well as at relapse (MOLT-4). This may prove
to be an important fact, as hypomethylating agents and HDAC-inhibitors may be clinically active
at first line therapy (induction therapy) and also at ALL relapse (in leukemic cells resistant to
conventional therapy). However, the ability to induce apoptosis in a significant number of cells
was obtained only with Trichostatin A, whereas Decitabine alone had mainly anti-proliferative
properties. Although both effects are significant from the therapeutic point of view, this may
indicate that the demethylation of certain genes may contribute less to the induction of apoptosis
than the chromatin remodeling induced by the HDACi. Nevertheless, as referred above, both
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epigenetic mechanisms act in concert and it is possible that the inhibition of HDACs opens the
chromatin and allows the intracellular molecular machinery to reach the previously inaccessible
segments of the DNA sequence, resuming translation of potentially silenced tumor – suppressor
genes. This fact was confirmed in this work, as incubation of MOLT-3 and MOLT-4 cells with
Trichostatin A leads to a decrease of the degree of p15 methylation as compared to control
(figure 8A). It is therefore evident that both tested drugs are able to reduce the density of methyl
groups associated with gene promoter regions that are relevant to cell cycle progression and,
therefore, have the potential to restore relevant gene function in ALL. Further work, regarding
the study of downstream molecular pathways, could provide solid evidence to support this
hypothesis.
It is interesting that although Trichostatin A is more effective at reducing cell viability/density,
Decitabine showed a higher efficacy at reducing the methylation status of p15, comparable to the
simultaneous association of both drugs, but was less efficient of inducing apoptosis. This may
indicate that, in these cell lines, Trichostatin induces cell death by other mechanisms that may be
more relevant than cell cycle control through re-activation of p15. Although methylation of p16
is known to have an important role in several malignancies (Cortesão et al., 2009), our
experiments failed to show amplification of the methylated gene, even in control conditions. This
may mean that this gene is poorly methylated in these ALL cell models. This could also be due
to poor experimental conditions, degraded reagents or inadequate primers, as could be the case of
p53. However, according to the provider of the cell lines, MOLT-4 cells do not express p53,
which has a mutation in codon 248. Whether that mutation is responsible for silencing the gene
is unknown to us. However, based on the data obtained here, we can conclude that, in this case,
p53 silencing is not due to DNA methylation or histone de-acetylation. We intend to explore
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further the effects of these drugs on p16 and p53 by using different experimental settings that can
provide a solution to the problems encountered.
There are more than 300 registered clinical trials (http://www.clinicaltrials.gov) at various
stages using these two classes of molecules in various types of cancer, including hematologic
malignancies. Potential therapeutic schemes include monotherapy as well as the combination
with conventional and new drugs.  In fact, one of the most relevant discoveries in this field was
the potential for a mechanistic synergy between hypomethylating agents and HDACis , which, if
transposed to clinical settings, will have a great therapeutic value (Claus et al., 2003; Fenaux ,
2005; Sarmento-Ribeiro et al., 2008). The most interesting result obtained in this study was the
synergistic effect achieved with the association of drugs and its dependence on the sequence of
drug administration. This was previously known in AML (Shaker et al., 2003) and has been
subject of tests in clinical settings (Miller et al., 2001; Gore et al., 2006). In our work, no
additive effect was observed with simultaneous incubation or when Trichostatin was added after
Decitabine: cell death levels were comparable to control conditions. However, when cells were
incubated with Decitabine after 4 hours of incubation with Trichostatin, a more than additive
effect was evident. This result contradicts some results previously obtained by others (Cameron
et al., 1999). The leading hypothesis states that the interaction among mechanisms of epigenetic
regulation obeys to a two step model. First, dense (but not partial) methylation excludes
activating complexes with acetylase activities and forbids binding of transcription factors.
Second, methyl cytosine-binding proteins bind histone deacetylases to the methylated CpG
islands, further repressing transcription. In this scenario, Trichostatin A could not reverse gene
silencing until some degree of demethylation allows active transcription complexes with
acetylase activities to bind promoter regions and reverse silencing (Baylin et al., 2000). Our
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work does not exclude the fundamental steps described in the model above, but points out that
demethylating agents may not be able to reach methylated DNA sequences trapped in coiled
segments of chromatin. If this is the case in ALL, acetylation of histones must precede
demethylation, allowing chromatin to open and leave DNA segments accessible. This is our
hypothesis, which we intend to further explore in future works. The mechanism of action of epi-
drugs is not a simple one. Moreover, the ability to modulate the epigenetic matrix may not be
enough, as different epi-drugs have not shown the same efficacy under similar conditions. In
addition, the main action mechanism of some of these molecules may not involve only
epigenetic changes (Flotho et al., 2009), and the capacity to activate apoptotic pathways may be
another possibility. In fact, our results show typically apoptotic morphological changes in cells
treated with epigenetic modulators. The leading, unifying theory is that both agents may exert
their effects by reversing methylation of promoter regions (Baylin, 2005). Beyond mechanistic
discussions, these facts may have clinical consequences, as the use of combination schemes not
only increases the effectiveness of the treatment but also allows the use of lower doses, inducing
less side effects (Lohrum et al., et al., 2007)
Certain characteristics of cancer cells, such as increased proliferation and deregulation of cell
cycle, are equivalent to some properties of human embryonic stem cells (hES), which has lead to
the conclusion that these cells can have a tendency to form tumors and sustain tumor grouth
(Clarke et al., 2006; Ohm et al., et al., 2007). However, recent results show that gene silencing is
tightly controlled in hES cells and differentiated cells but not in cancer cells, leading to a
significantly different methylation profile, where the referred similarities are, consequently,
merely coincidental (Bibikova et al., 2006). Understanding the control mechanisms is essential
as their recovery may reverse silencing of key genes and, as a result, the malignant phenotype
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(Felsher, 2003). However, that may be a difficult task as the role of DNA methylation may be
too complex, whose consequences are still difficult to predict (Bird, 2002; Laird, 2005).
Early techniques used to study methylation status of DNA regions were limited to Southern
blotting after digestion of genomic DNA with methylation – sensitive restriction enzymes. New
methods have risen, giving scientists the tools to analyze single genes, as well as the whole
epigenome of cells (Esteller, 2007). Here we have used methylation-specific PCR (MSP). First
described in 1992 by Frommer and colleagues (Frommer 1992), this method consists in the
amplification of the DNA after treatment with bissulfite – which transforms unmethylated (but
not methylated) cytosines into uracils –using different primers for methylated and unmethylated
DNA sequences. Differences in amplification reflect the differences in methylation. This
procedure, although not suitable for genome-wide studies (Schones et al., 2008), has proven to
be a robust, specific, sensitive and rapid method to evaluate small numbers of genes (Hermanet
al., 1996) and is the basis for the most recent and widely used techniques (Galm et al., 2005;
Schones et al., 2008).
The nonspecific activation of genes in normal cells induced by epi-drugs has raised some
concerns regarding the clinical applications of these agents: the reversal of DNA methylation
could lead to chromosomal instability, loss of chromosomal integrity, and facilitate mutation
(Esteller, 2007). However, treatment of leukaemia patients with Azacytidine failed to show
development of a secondary malignancy in follow-up studies (Egger et al., 2004). Furthermore,
the advantage of this kind of targeted therapy is that it takes advantage out of the dependence of
cancer cells on the transcripts of oncogenes for growth and survival. This kind of targeted
treatment underlies the specificity of these drugs, sparing normal cells, making them attractive
subjects of investigation (Voltz et al., et al., 2007; Croce, 2008). The results obtained in vitro
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may not have the desired equivalence in vivo, a fact that is related to several constraints
associated with the complexity of living organisms. This may constitute one of the limitations of
this work. However, immortal cell cultures are homogeneous, simple models of disease, allowing
an accurate characterization of molecular processes and therapeutic mechanisms. The results
described in this work leave clues that may help devise rational studies in animal or human
subjects and further support the increasing complexity of therapeutic schemes.
 Carcinogenesis is most probably a multistep process where several oncogenes, tumor-
suppressor genes or microRNA genes suffer alterations: a sequence of initiation and progression
events, genetic and epigenetic, which lead to the malignant phenotype (Croce, 2008). In most
cases, these alterations are acquired during lifetime and may be the result of environmental
pressures acting over cells (Jaenisch et al., 2003; Weidman et al., et al., 2007). In this work, we
have chosen to study some of the most relevant genes in leukemogenesis in particular, and in
carcinogenesis in general. Other genes may prove to be important targets of epi-drugs in ALL.
However, we believe that the proof of the interference of such drugs with the cell cycle is an
important fact, aiding to the understanding of the molecular events underlying responses on
cellular or clinical levels. Ultimately, this knowledge may provide further insight about complex
diseases and contribute to the design of novel preventive, diagnostic or therapeutic approaches
(Laird, 2005; Galm et al., 2005; Herceg et al., et al., 2007; Gal-Yam et al., 2008). Thorough
analysis if the molecular pathways involved in the response to such promising drugs may provide
the necessary clues to answer such questions and devise rational trials in the future.
This study suggests that epigenetic modulation might constitute a new approach to the
treatment of lymphoid malignancies, namely ALL-T. However, the choice of the optimal
schedule of drugs administration seems to be crucial to the success of the therapy.
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